PTC Therapeutics Inc PTCT.OQ PTCT.O is expected to show a fall in quarterly revenue when it reports results on November 4 for the period ending September 30 2025
The Warren New Jersey-based company is expected to report a 5.9% decrease in revenue to $185.251 million from $196.79 million a year ago, according to the mean estimate from 13 analysts, based on LSEG data.
LSEG's mean analyst estimate for PTC Therapeutics Inc is for a loss of $1.37 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy," 5 "hold" and 1 "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for PTC Therapeutics Inc is $70.00, about 2.7% above its last closing price of $68.11
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | -0.96 | -1.06 | -0.83 | Beat | 21.8 |
Mar. 31 2025 | -0.89 | -0.21 | 10.04 | Beat | 4,835.8 |
Dec. 31 2024 | -0.50 | -0.66 | -2.15 | Missed | -227.7 |
Sep. 30 2024 | -1.46 | -1.44 | -1.39 | Beat | 3.6 |
Jun. 30 2024 | -1.05 | -1.05 | -1.27 | Missed | -21.1 |
Mar. 31 2024 | -1.39 | -1.24 | -1.20 | Beat | 3.3 |
Dec. 31 2023 | 0.42 | 0.50 | -0.24 | Missed | -148.4 |
Sep. 30 2023 | -1.16 | -1.17 | -1.76 | Missed | -50.4 |
This summary was machine generated October 31 at 22:43 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)